Previous 10 | Next 10 |
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma PR Newswire ~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadj...
2024-05-07 06:06:55 ET More on IDEAYA Biosciences Ideaya Biosciences: A Strong Bet In Targeted Oncology Ideaya inks clinical trial pact with Merck IDEAYA a new Buy at BTIG on underappreciated pipeline Seeking Alpha’s Quant Rating on IDEAYA Biosciences ...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd , and targeting neoadjuvant UM update in over 30 patie...
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...
2024-03-12 09:29:51 ET More on Ideaya, Merck, etc. Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript) Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Div...
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA ® ...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...